Routine Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials.

ABSTRACT: The risk of periprocedural stroke with TAVR remains a significant concern. Cerebral embolic protection (CEP) devices have been developed to mitigate this risk, but their clinical benefit remains uncertain. We aimed to evaluate the effectiveness and safety of routine CEP use during TAVR through a meta-analysis of randomized controlled trials (RCTs). A systematic search of PubMed, EMBASE, and ClinicalTrials.gov was conducted from inception to May 22, 2025, to identify RCTs comparing CEP versus standard care during TAVR. The primary outcome was stroke (including disabling and nondisabling strokes). Secondary outcomes included disabling stroke, new ischemic lesions on post-TAVR brain magnetic resonance imaging, all-cause mortality, major vascular complications, life-threatening bleeding, and a

SUBMITTER: Ismayl M 

PROVIDER: S-EPMC12354806 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature